Indian CROs Expect To Benefit From Global Economic Angst
This article was originally published in PharmAsia News
Executive SummaryClinical research organizations in India believe they are invulnerable to the impact of a recession expected to affect much of the world. In fact, new research predicts India's CRO market will triple over the next two years to a $600 million industry as large drug makers outsource more of their trials to India in the face of credit restrictions at home. The researchers noted the cost of even a simple trial in India is as much as 20 percent cheaper than in the United States, with the most complex ones saving more than half the U.S. cost. (Click here for more
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.